Key result
Recent advances in surgical, minimally invasive, and transcatheter heart valve technologies have significantly expanded therapeutic options for patients with aortic and mitral valve disease.
This review provides a comprehensive overview of emerging surgical and transcatheter technologies for the treatment of aortic and mitral valve disease, offering a scientific basis for their adoption into clinical practice.
May guide individualized valve therapy decisions; leaves open the need for randomized trials to confirm benefits.
The burden of heart valve disease among adults is enormous in the developed world. Increased life expectancy and age-related valvular degeneration remain the predominant contributors to heart valve dysfunction, which if uncorrected lead to congestive heart failure and increased morbidity and mortality. Clinical evidence on the detrimental impact of valve disease on both pediatric and adult populations has fueled growing interest in diagnosis and therapy for heart valve disease, and also significant financial investment from hospitals and medical device manufacturers in hybrid operating rooms and novel medical device technologies. A wide array of surgical, minimally invasive and percutaneous heart valve technologies are available today, which have significantly enlarged the surgeon's armamentarium, and revolutionized the traditional role of a surgeon in correcting such lesions. Amid this revolution in heart valve technologies, we present recent advances in heart valve therapies, critically appraise their clinical need, and finally discuss the clinical experience and outcomes of some of these technologies. The expected outcome of this review is to provide the clinical reader with a reasonable scientific basis to enable appropriate adoption of these technologies into their clinical practice.
No takes yet. Share an insight, caveat, or question.
Padala et al. (2011) conducted a review in Heart valve disease. Novel heart valve therapies was evaluated. Recent advances in surgical, minimally invasive, and transcatheter heart valve technologies have significantly expanded therapeutic options for patients with aortic and mitral valve disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: